A study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure: The ACCLAIM trial rationale and design

Q2 · MEDICINE

Article

Author: Jean Lucien Rouleau ; Robert C. Bourge ; Guillermo Torre-Amione ; Craig Pratt ; John A. Geddes ; Wilson S. Colucci ; Barry Greenberg ; Lemuel A Moye ; James B. Young ; Francois Sestier ; Agnes J. Nemet

BACKGROUNDEvidence has accumulated regarding the importance of inflammatory mediators in the development and progression of heart failure (HF). Although targeted anticytokine treatment strategies, specifically antitumour necrosis factor-alpha, have yielded disappointing results, this may simply reflect the redundancy of the cytokine cascade and the fact that antitumour necrosis factor-alpha therapies do not stimulate increased activity of the anti-inflammatory arm of the immune system. Ex vivo exposure of autologous blood to controlled oxidative stress and subsequent intramuscular administration is a device-based procedure shown in experimental studies to have a broad-spectrum effect on a number of immune mediators. These studies have demonstrated that this approach downregulates inflammatory cytokines, whereas several anti-inflammatory cytokines are increased. In a feasibility study of 73 patients with moderate to severe HF, active therapy (versus placebo) had a significant benefit on both mortality and hospitalization, and was not associated with adverse hemodynamic or metabolic effects.METHODSThe Advanced Chronic heart failure CLinical Assessment of Immune Modulation therapy (ACCLAIM) trial is a multicentre, randomized, double-blind, placebo-controlled clinical trial of New York Heart Association functional class II to IV chronic HF patients with left ventricular ejection fraction of 30% or less. Enrolling approximately 2400 subjects at 177 sites, the primary end point of the study was the cumulative incidence (time to first event) of the combined end point of total mortality or hospitalization for cardiovascular causes. The study was completed in late 2005, when 701 primary end point events had occurred and all patients had been treated for six months.CONCLUSIONSIf the ACCLAIM trial confirms earlier results, this approach represents a novel nonpharmacological treatment for HF that targets a pathogenic mechanism contributing to progression of this syndrome not addressed by current therapies.

01 Dec 2000·Journal of Low Frequency Noise, Vibration and Active Control

Digit Skin Temperature Test for Peripheral Circulation Evaluation

Author: Ibanez, D ; de Veber, G ; Pelmear, P.L.

A test procedure for evaluating vasospasm in hand digits using cold water immersion at 15°C for a period of 10 minutes is described, and the result of initial and repeat tests on 25 subjects who volunteered for a control group study are reported. Digit skin temperatures were continuously recorded and the recovery temperatures were noted while the hands were immersed and for a further 10 minutes afterwards in air. Five from their history and test results were determined to have Raynaud's disease or Constitutional White Finger, and a further 5 subjects with no history of cold hands or Raynaud's phenomenon had non-repeatable test results indicative of an asymptomatic sub-clinical state. A statistical analysis of the results from the 15 normal control subjects provides reference data (means and standard deviations) for the maximum skin temperature at 10 minutes immersion, and the skin recovery temperatures post-cold stress at 1 minute intervals in air. This objective test is frequently used for evaluating cold induced vasospasm in hand digits, and the normative data provided will enable abnormal subjects to be identified. Additional reference data is provided for use with vibration exposed workers to permit the severity of the vasospasm to be graded in accordance with the Stockholm vascular scale for Hand-arm Vibration Syndrome (HAVS).

Neutralization of Th2 cytokines in therapy of cardiovascular pathology

Author: Bolton, A. E. ; Mandel, A.

A review on the role of cytokines produced by T-helper 2 (Th2) cells in inflammatory responses, and involvement of specific Th2 cytokine signaling in cardiac and arterial pathol., particularly relating to endothelial function, atherogenesis and thrombosis.

News (Medical) associated with Intellipharmaceutics International, Inc.

13 Mar 2024

·www.biospace.com

Intellipharmaceutics International Inc. Announces Transfer of Listing to NEX and New Stock Option Plan

TORONTO, ON / ACCESSWIRE / March 13, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) - ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announces its listing on NEX, a separate board of the TSX Venture Exchange (the "TSXV"). The Company has applied to transfer its listing from the TSX to TSXV as previously disclosed. However, as the Company is currently subject to a Cease Trade Order issued by the Ontario Securities Commission for failure to satisfy financial reporting requirements (as previously disclosed on March 6, 2024), the Company will be transferred to NEX. If the Company comes back into good standing with the securities commissions and its continuous disclosure obligations, it can apply for a reactivation of its listing on TSXV. The Company will be voluntarily delisted from the TSX at the close of March 25, 2024 and will be listed on the NEX at the open of March 26, 2024. According to Section 720 of the TSX Company Manual, shareholder approval is not required as an acceptable alternative market will exist for the listed securities. Upon the transfer of its listing to NEX, the trading symbol of the Company's common shares will change from "IPCI" to "IPCI.H". The .H symbol extension differentiates NEX symbols from other symbols on the main stock list of the TSXV. There is no change in the Company's name or CUSIP number, and no consolidation of capital. The Company's common shares will also continue to be listed on the OTCQB Marketplace in the United States under the symbol "IPCIF". The Company also announces that the TSXV has approved a new stock option plan of the Company (the "SOP") that will be subject to shareholder approval at the next annual meeting of shareholders of the Company.The new SOP is a rolling plan (with 10% of shares reserved for issuance), which will replace all existing security based compensation plans of the Company. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. About Intellipharmaceutics Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company's patented Hypermatrix ™ technology is a multidimensional controlled-release drug delivery platform that can be applied to a wide range of existing and new pharmaceuticals. Intellipharmaceutics has developed several drug delivery systems based on this technology platform, with a pipeline of products (some of which have received FDA approval) in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Company's abuse-deterrent oxycodone hydrochloride extended-release formulation ("Oxycodone ER") based on its proprietary nPODDDS™; novel Point Of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin™; XR (pregabalin extended-release capsules). Cautionary Statement Regarding Forward-Looking Information Certain statements in this news release constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario) (collectively, "forward-looking statements"). These statements include, without limitation, statements expressed or implied regarding the potential future listing of the Shares on the TSXV, which remains subject to approval by the TSXV, the Company's expectation that it will regain compliance with its continuous disclosure obligations, including with respect to results and timing of the processes related to any of the foregoing. In some cases, you can identify forward-looking statements by terminology such as "appear", "unlikely", "target", "may", "will", "should", "expects", "plans", "plans to", "anticipates", "believes", "estimates", "predicts", "confident", "prospects", "potential", "continue", "intends", "look forward", "could", "would", "projected", "set to", "seeking" or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of our forward-looking statements. You should not place undue reliance on our forward-looking statements, which are subject to a multitude of known and unknown risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those stated in or implied by the forward-looking statements. Risks and uncertainties relating to us and our business include the Company's inability to list its Shares on the TSXV or to regain compliance with continuous disclosure requirements and lifting any applicable cease trade order, and other risk factors described under the "Risk Factors" section of our latest annual information form, our latest Form 20-F, and our latest Form F-1 and Form F-3 registration statements (including any documents forming a part thereof or incorporated by reference therein), as amended, as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada and the U.S., which are available on and The forward-looking statements herein reflect our current views with respect to future events and are based on what we believe are reasonable assumptions as of the date of this document and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Trademarks used herein are the property of their respective holders. Unless the context otherwise requires, all references to "we," "us," "our," Intellipharmaceutics," and the "Company" refer to Intellipharmaceutics International Inc. and its subsidiaries. CONTACT INFORMATION Company Contact: Intellipharmaceutics International Inc. Isa Odidi Chief Executive Officer 416.854.9090 investors@intellipharmaceutics.com SOURCE: Intellipharmaceutics International Inc. View the original press release on accesswire.com

26 Feb 2024

·www.biospace.com

Intellipharmaceutics Announces Its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form

TORONTO, ON / ACCESSWIRE / February 26, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that its annual audited financial statements for the fiscal year ended November 30, 2023, related management's discussion and analysis and accompanying Chief Executive Officer and Chief Financial Officer certificates and annual information form for the fiscal year ended November 30, 2023 (collectively, the "Required Filings") due February 28, 2024 (the "Filing Deadline") will not be filed by the Filing Deadline. The Company will be delayed in filing the Required Filings by the Filing Deadline as required under applicable Canadian securities laws. However, the Company is working very hard to facilitate the performance of the audit of the Company's financial statements in order to Required Filings as soon as they are available and within a reasonable period. The Company expects that the Ontario Securities Commission (the "OSC") will, following the Company's failure to make the Required Filings by the Filing Deadline, issue a general "failure to file" cease trade order pursuant to Multilateral Instrument 11-103 - Failure to File Cease Trade Orders in Multiple Jurisdictions in respect of the securities of the Company (the "CTO"). The Company confirms that there are no insolvency proceedings against it and no material information relating to its affairs that has not been generally disclosed. The Company will continue to operate in the normal course of business, fulfilling its commercial contracts and obligations and intends to immediately apply for a revocation of the CTO as soon as the Required Filings are duly About Intellipharmaceutics Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company's patented Hypermatrix™ technology is a multidimensional controlled-release drug delivery platform that can be applied to a wide range of existing and new pharmaceuticals. Intellipharmaceutics has developed several drug delivery systems based on this technology platform, with a pipeline of products (some of which have received FDA approval) in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Company's abuse-deterrent oxycodone hydrochloride extended-release formulation ("Oxycodone ER") based on its proprietary nPODDDS™ novel Point Of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin™ XR (pregabalin extended-release capsules). Cautionary Statement Regarding Forward-Looking Information Certain statements in this document constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements include, without limitation, statements expressed or implied regarding our expectations related to the filing of our Required Filings and the timing thereof; statements expressed or implied regarding the listing of the Shares on the TSXV and the voluntary delisting of the Shares from the TSX, each of which remain subject to approval by the TSXV and TSX, respectively, and any expectations, including with respect to results and timing of the processes related to any of the foregoing; our plans, goals and milestones, status of developments or expenditures relating to our business, plans to fund our current activities; and statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future sales, revenues and profitability, projected costs and market penetration and risks or uncertainties related to our ability comply with OTCQB Venture Market and TSXV requirements. In some cases, you can identify forward-looking statements by terminology such as "appear", "unlikely", "target", "may", "will", "should", "expects", "plans", "plans to", "anticipates", "believes", "estimates", "predicts", "confident", "prospects", "potential", "continue", "intends", "look forward", "could", "would", "projected", "set to", "seeking" or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of our forward-looking statements. You should not place undue reliance on our forward-looking statements, which are subject to a multitude of known and unknown risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those stated in or implied by the forward-looking statements. Risks and uncertainties relating to us and our business can be found in the "Risk Factors" section of our latest annual information form, our latest Form 20-F, and our latest Form F-1 and Form F-3 registration statements (including any documents forming a part thereof or incorporated by reference therein), as amended, as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada and the U.S., which are available on and . The forward-looking statements reflect our current views with respect to future events and are based on what we believe are reasonable assumptions as of the date of this document and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Trademarks used herein are the property of their respective holders. Unless the context otherwise requires, all references to "we," "us," "our," Intellipharmaceutics," and the "Company" refer to Intellipharmaceutics International Inc. and its subsidiaries. CONTACT INFORMATION Company Contact: Intellipharmaceutics International Inc. Isa Odidi Chief Executive Officer 416-854-0909 iodidi@intellipharmaceutics.com SOURCE: Intellipharmaceutics International Inc. View the original press release on accesswire.com

08 Feb 2024

·www.biospace.com

Intellipharmaceutics International Inc. Announces Stock Option Grant - February 08, 2024

TORONTO, ON / ACCESSWIRE / February 8, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announces that, the Company has issued 1,910,000 common share purchase options (the "Options", and each an "Option") pursuant to the Company's stock option plan (the "Plan"). The Company issued 1,910,000 Options to certain directors, officers and employees of the Company, who are eligible to receive the Options under the Plan. Each Option grants the holder the right to purchase one Common Share at a purchase price of Cdn $0.094 per Common Share for a period of 10 years from the date of issue. Accordingly, the Options expire February 5, 2034. The Options will vest: (i) 50% immediately; (ii) 25% on the first anniversary of the grant; and (iii) 25% on the second anniversary of the grant. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. About Intellipharmaceutics Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company's patented Hypermatrix™ technology is a multidimensional controlled-release drug delivery platform that can be applied to a wide range of existing and new pharmaceuticals. Intellipharmaceutics has developed several drug delivery systems based on this technology platform, with a pipeline of products (some of which have received FDA approval) in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Company's abuse-deterrent oxycodone hydrochloride extended-release formulation ("Oxycodone ER") based on its proprietary nPODDDS™; novel Point Of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin™; XR (pregabalin extended-release capsules). Cautionary Statement Regarding Forward-Looking Information Certain statements in this news release constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario) (collectively, "forward-looking statements"). These statements include, without limitation, statements expressed or implied regarding the listing of the Shares on the TSXV and the voluntary delisting of the Shares from the TSX, each of which remain subject to approval by the TSXV and TSX, respectively, and any expectations, including with respect to results and timing of the processes related to any of the foregoing. In some cases, you can identify forward-looking statements by terminology such as "appear", "unlikely", "target", "may", "will", "should", "expects", "plans", "plans to", "anticipates", "believes", "estimates", "predicts", "confident", "prospects", "potential", "continue", "intends", "look forward", "could", "would", "projected", "set to", "seeking" or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of our forward-looking statements. You should not place undue reliance on our forward-looking statements, which are subject to a multitude of known and unknown risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those stated in or implied by the forward-looking statements. Risks and uncertainties relating to us and our business include the Company's inability to list its Shares on the TSXV and to voluntarily delist its Shares from the TSX and other risk factors described under the "Risk Factors" section of our latest annual information form, our latest Form 20-F, and our latest Form F-1 and Form F-3 registration statements (including any documents forming a part thereof or incorporated by reference therein), as amended, as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada and the U.S., which are available on and . The forward-looking statements herein reflect our current views with respect to future events and are based on what we believe are reasonable assumptions as of the date of this document and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Trademarks used herein are the property of their respective holders. Unless the context otherwise requires, all references to "we," "us," "our," Intellipharmaceutics," and the "Company" refer to Intellipharmaceutics International Inc. and its subsidiaries. CONTACT INFORMATION Company Contact: Intellipharmaceutics International Inc. Isa Odidi Chief Executive Officer 416.854.9090 investors@intellipharmaceutics.com SOURCE: Intellipharmaceutics International Inc. View the original press release on accesswire.com

100 Deals associated with Intellipharmaceutics International, Inc.

100 Translational Medicine associated with Intellipharmaceutics International, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 24 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Quetiapine Fumarate ( 5-HT2A receptor x D2 receptor )	Schizophrenia More	Approved
VAS-972	Psoriasis More	Discontinued
VP-025 ( Cytokine receptors )	Nervous System Diseases More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis